AAIC 2025 Preclinical Results of Anti-Tau Antibody MK-2214 in Alzheimer Disease: Jonathan Sugam, PhD
The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]
